Therapeutic Solutions International Develops Microemulsion Formulation of Alpha Lipoic Acid for Intranasal Delivery
Therapeutics Solutions International, Inc. recently announced successful production of a stable microemulsion of Alpha Lipoic Acid (ALA) from ingredients Generally Regarded as Safe (GRAS). The microemulsion, which is a form of racemic alpha lipoic acid containing microparticles of ALA, is an ingredient in the company’s issued US Patent No.: 9,682,047 along with pterostilbene, the active ingredient in the company’s patented ProJuvenol product.
Like pterostilbene, ALA is a very potent anti-oxidant and is also known as – lipoic acid, alpha lipoic acid (ALA), and thioctic acid, an organosulfur compound derived from octanoic acid and appears to be an ideal substance in the treatment of oxidative brain and neural disorders involving free radical processes. Thiols like ALA are central to antioxidant defense in brain and other tissues.
It is believed that Reactive Oxygen Species (ROS) are involved in many different types of pathologic conditions in the brain and neural tissue. Brain disorders involving free radical injury have few neuropharmacological intervention strategies for treatment of these conditions. ALA as a potent antioxidant, can regenerate through redox cycling other potent antioxidants like vitamin C and vitamin E, and to raise intracellular glutathione levels. The most important thiol antioxidant, glutathione, cannot be directly administered, whereas alpha lipoic acid can.
“There are numerous publications showing promising effects of alpha lipoic acid in preclinical models of neurodegenerative conditions such as multiple sclerosis, stroke, and Alzheimer’s Disease,” said James Veltmeyer, MD, Chief Medical Officer of Therapeutic Solutions International. “By providing alternative delivery mechanisms of this agent, we believe we may be offering novel approaches towards addressing these terrible conditions.”
“Treatment of chronic neurodegenerative conditions require a multi-factorial approach that addresses various molecular pathologies involved in the condition,” added Tim Dixon, CEO of Therapeutic Solutions International. “By providing novel formulations capable of augmenting delivery of agents across the blood brain barrier, we aim to provide physicians new tools in their arsenal in treatment of conditions such as multiple sclerosis, Alzheimer’s, and post-stroke recovery.”
The Company’s corporate website is www.therapeuticsolutionsint.com. Our new products can be viewed on www.projuvenol.com and products can be ordered at www.youcanordernow.com.
Total Page Views: 1701
